Aspira Q1 revenue $2.2M; OvaWatch volume up 114% YoY

Aspira Women's Health Inc.

2024-Q1 EPS reported -$0.39 vs consensus -$0.34 ▼ miss (-16.1%)

Product revenue $2.2M, down 4% YoY; OvaSuite volume 5,829 units (-7%).
Gross profit margin improved to 56% from 51% in Q1 2023.
Cash used in operating activities $4.4M, down 22% YoY; 2024 target stays $15-18M.
OvaWatch volume grew 114% YoY; longitudinal monitoring feature launched.
New Anthem Blue Cross CA coverage agreement for OvaSuite effective June 1, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

Aspira Women's Health Inc. reported first quarter ended March 31, 2024 results: revenue $2.2 million. Guidance reaffirmed.

Period: first quarter ended March 31, 2024
Revenue: $2.2 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

by reference language in such filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Aspira Women’s Health Reports First Quarter 2024 Financial Results Q1 2024 OvaSuite SM revenue of $2.2 million and volume of 5,829 units Q1 2024 cash utilization of $4.4 million, a decrease of 22% compared to Q1 2023 Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN,

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Aspira Women's Health Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-060049

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.